"The results from anacetrapib and evacetrapib [in phase II studies] make a blood pressure increase [caused by either drug] unlikely," noted Dr. Schwartz. In addition, "dalcetrapib has no effect on LDL cholesterol, while anacetrapib and evacetrapib both increase LDL considerably."
But another possibility – that any agent that works primarily by raising HDL cholesterol may have little clinical benefit – cannot be dismissed based on current knowledge, Dr. Schwartz warned.
"The modified risk produced by raising HDL cholesterol may not be significant compared with other treatments that patients get," Dr. Schwartz cautioned. In the dal-OUTCOMES trial, the average LDL cholesterol level was 76 mg/dL. Against this background, "even in the quartile of about 1,600 patients in the dalcetrapib group who achieved the highest level of HDL cholesterol, a level of about 70-75 mg/dL, we saw no apparent reduction in risk."
Concurrent with Dr. Schwartz’s report at the meeting, the results of the dal-OUTCOMES study were published online (N. Engl. J. Med. 2012 Nov. 9 [doi: 10.1056/NEJMoa1206797]).
The dal-OUTCOMES trial was sponsored by Hoffman-La Roche, the company developing dalcetrapib. Dr. Schwartz said that he has received grant support from Anthera, Resverlogix, Roche, and Sanofi. Dr. Tall had no disclosures.